An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients
NCT06923891
·
clinicaltrials.gov ↗
PHASE4
Phase
NOT_YET_RECRUITING
Status
172
Enrollment
OTHER
Sponsor class
Conditions
Schizophrenia
Interventions
DRUG:
Xanomeline/Trospium
Sponsor
Vanguard Research Group
Collaborators
[object Object]